Opinion|Videos|May 6, 2024
A New Era in PAH Treatment?
Author(s)Marius Hoeper, MD
An expert on pulmonary arterial hypertension discusses the potential impact of emerging therapies, including sotatercept, ralinepag, and inhaled imatinib.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- What is your assessment of the potential clinical impact of new or emerging pulmonary arterial hypertension (PAH) therapies, such as sotatercept, ralinepag, and inhaled imatinib, in terms of reducing hospitalizations or need for supportive care and improving long-term patient outcomes and quality of life?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
How Do GLP-1 Agonists Fit Into Stroke Care?
3
5 Things to Know About the Oral GLP-1 Era
4
Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention
5
